Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Humatrope approved for new indication in U.S.

Aug. 23, 1996

Update on Biotech Holdings' Diab II

Aug. 23, 1996

Alteon initiates phase III trials of pimagedine

Aug. 23, 1996

Johnson & Johnson continues pramlintide collaboration

Aug. 23, 1996

Pramlintide shows positive safety/efficacy profile in phase II

Aug. 23, 1996

Humalog launched on U.S. market

Aug. 23, 1996

Hematopoiesis-stimulating compounds from Nycomed Pharma

Aug. 23, 1996

RIIbeta: Potential antiobesity drug target

Aug. 23, 1996

CCK-A agonist from Glaxo Wellcome

Aug. 23, 1996

New hypolipidemic agent from Schering-Plough

Aug. 23, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...